I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol

In October 2020, the FLCCC Alliance developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. It’s centered around ivermectin, a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and has won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical discovery of a rapidly growing published medical evidence base, demonstrating ivermectin’s unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19. Ivermectin is not yet FDA-approved for the treatment of COVID-19, but on Jan 14, 2021, the NIH changed their recommendation for the use of ivermectin in COVID-19 from “against” to “neutral”. (see our  press release).

Our life-saving MATH+ Hospital Treatment Protocol for COVID-19 (available in several languages), created in March 2020, is intended for hospitalized patients. The recently developed I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 (this page) is designed for use as a prophylaxis and in early outpatient treatment, for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved (except ivermectin), inexpensive, readily available and have been used for decades with well-established safety profiles.

Please download and share our I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19. (It is currently being translated into several languages).

Below are a list of links to our one-page summary of the latest evidence for the protocol, plus videos of FLCCC Alliance doctors discussing the emerging evidence for the use of ivermectin in the prophylaxis and treatment of COVID-19, and a short list of up-to-date studies and clinical trials on this topic.

• Our comprehensive review of the emerging evidence for ivermectin use in our I-MASK+ protocol
• A one-page summary of the scientific review on ivermectin above
• Dr. Paul Marik’s comprehensive meta-analysis of COVID-19 therapeutics
• An introductory video explaining the review on ivermectin by Dr. Pierre Kory
• Dr. Paul Marik’s recent lecture on I-MASK+
• Invited Grand Rounds Lecture on ivermectin by Pierre Kory

Please also regard Dr. Paul Marik’s latest

• An FLCCC Alliance guide to the management of COVID-19 – An overview of the MATH+ and I-MASK+ protocols